PUTRAJAYA — The supply of medicines in the country is currently stable and under control despite the US-Israel conflict with Iran and its spillover in the region, the Health Ministry (MOH) said today.
The short-term impact of the conflict is “minimal” based on current assessments, as MOH facilities stock medicines for between one and three months based on usage requirements, the ministry said in a statement.
“The stock level of medicines at MOH facilities is also supported by additional buffer stock of up to two months at the concession company level for medicines supplied through the logistics concession,” it said.
Local manufacturers also have raw material stock sufficient for up to three months, while finished products are available for about two months, MOH added, citing feedback from the local pharmaceutical industry.
Monitoring of medicine supply is also carried out continuously through existing mechanisms, including the supply disruption reporting system by Product Registration Holders (PRH), managed by the National Pharmaceutical Regulatory Agency (NPRA).
“As of March 22, 2026, no increasing trend has been detected in PRH reports involving disruptions in the supply of medicines,” the ministry said.
Meanwhile, importers are also carrying out close monitoring of their respective supply chains to ensure the continuity of the medicine supply.
MOH said that it will continue to closely monitor developments and remains committed to taking proactive measures to ensure the security of the medicine supply for the people.
“This includes the establishment of a task force comprising representatives from the pharmaceutical industry and relevant stakeholders to monitor and ensure the security of medicine supply, particularly medicines listed under the National Essential Medicines List (NEML) in Malaysia,” it said. – March 23, 2026